Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 11:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 400 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Communicable Diseases in Children Clear all
Recruiting No phase listed Observational

Pregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure

NCT06026969
View directory record Official record
Conditions
Lyme Disease, Post-Treatment Lyme Disease, Chronic Lyme Disease, Tick-Borne Infections, Pregnancy Complications, Child Development
Interventions
Neurodevelopmental assessments and follow-up
Other
Lead sponsor
Children's National Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 3, 2026, 11:00 AM EDT
Completed Phase 3 Interventional

Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV

NCT00086359
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, lamivudine, and zidovudine, Lamivudine/zidovudine, Lopinavir/ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
7
States / cities
Los Angeles, California • San Diego, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 3, 2026, 11:00 AM EDT
Not listed Phase 2 Interventional

Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV

NCT00017992
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir, Emtricitabine, Stavudine
Drug
Lead sponsor
Triangle Pharmaceuticals
Industry
Eligibility
3 Months to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Los Angeles, California • Jacksonville, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 3, 2026, 11:00 AM EDT
Completed Phase 1 Interventional

A Phase I Evaluation of Azidothymidine (AZT) in Children With Acquired Immune Deficiency Syndrome (AIDS) or AIDS Related Complex (ARC)

NCT00000701
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 12 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
2
States / cities
Miami, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 3, 2026, 11:00 AM EDT
Completed Phase 3 Interventional Results available

Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)

NCT04938830
View directory record Official record
Conditions
RSV Infection
Interventions
Clesrovimab, Palivizumab, Placebo
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
Up to 1 Year
Enrollment
1,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
29
States / cities
Long Beach, California • Orange, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 3, 2026, 11:00 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children

NCT05197075
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
DRV/COBI FDC
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 3, 2026, 11:00 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age

NCT00488345
View directory record Official record
Conditions
Bacterial Infections, Intra-Abdominal Infection, Pneumonia, Bacterial, Skin Diseases, Bacterial, Skin Diseases, Infectious
Interventions
Tygacil
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
8 Years to 11 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
18
States / cities
Long Beach, California • Oakland, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Oct 3, 2026, 11:00 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children

NCT00006325
View directory record Official record
Conditions
HIV Infections
Interventions
Peginterferon alfa-2b
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 16 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
15
States / cities
Long Beach, California • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 3, 2026, 11:00 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents

NCT00485264
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir poloxamer film coated tablet, Raltegravir chewable tablet, Raltegravir oral granules for suspension (20 mg/mL)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
30 Days to 18 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
29
States / cities
Alhambra, California • La Jolla, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 3, 2026, 11:00 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents

NCT00766597
View directory record Official record
Conditions
HIV Infections
Interventions
Vicriviroc
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
San Diego, California • Washington D.C., District of Columbia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 3, 2026, 11:00 AM EDT
Completed Phase 4 Interventional

Study of Blood Levels of Ceftaroline Fosamil in Children Who Are Receiving Antibiotic Therapy in the Hospital

NCT01298843
View directory record Official record
Conditions
Infections
Interventions
Ceftaroline fosamil
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
Up to 11 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
15
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 3, 2026, 11:00 AM EDT
Completed Phase 2 Interventional Results available

Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents

NCT00921557
View directory record Official record
Conditions
HIV Infection
Interventions
Alendronate, Placebo, Calcium carbonate/vitamin D
Drug · Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
11 Years to 24 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
7
States / cities
Los Angeles, California • Miami, Florida • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 3, 2026, 11:00 AM EDT
Completed Phase 4 Interventional

Study of the Use of Coated Venous Catheters in the Critically Ill Child

NCT00202813
View directory record Official record
Conditions
Children in the Pediatric Intensive Care Unit or General Pediatric Care Unit Requiring a Central Venous Catheter
Interventions
Cook Spectrum Pediatric Central Venous Catheter Anti-microbial Impregnated Polyurethane and Arrow Pediatric Central Venous Catheter
Device
Lead sponsor
Corewell Health West
Other
Eligibility
Up to 18 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 3, 2026, 11:00 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children

NCT04816643
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
Biological/Vaccine: BNT162b2 10mcg, BNT162b2 20mcg, BNT162b2 30mcg, Placebo, Biological/Vaccine: BNT162b2 3mcg
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
6 Months to 15 Years
Enrollment
11,837 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
90
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 67 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 3, 2026, 11:00 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®

NCT00258856
View directory record Official record
Conditions
Meningitis, Meningococcal Infection
Interventions
Polysaccharide Diphtheria Conjugate Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
7 Years to 15 Years
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
11
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Marietta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 3, 2026, 11:00 AM EDT
Completed Phase 2 Interventional

A Trial of Two Doses of 2',3'-Dideoxycytidine (ddC) in the Treatment of Children With Symptomatic HIV Infection Who Are Intolerant of AZT and/or Who Show Progressive Disease While on AZT

NCT00000653
View directory record Official record
Conditions
HIV Infections
Interventions
Zalcitabine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 18 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
32
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 3, 2026, 11:00 AM EDT
Completed Phase 1 Interventional

Cipro Inhaler for Cystic Fibrosis Children Ages 6-12

NCT00910351
View directory record Official record
Conditions
Pseudomonas Infection
Interventions
Ciprofloxacin (Cipro, BAYQ3939)
Drug
Lead sponsor
Bayer
Industry
Eligibility
6 Years to 12 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2013 · Synced Oct 3, 2026, 11:00 AM EDT
Terminated Phase 3 Interventional Results available

A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia

NCT01110421
View directory record Official record
Conditions
Pneumonia, Bacterial, Community-Acquired Infections, Nosocomial Infection, Pneumonia, Ventilator-Associated
Interventions
Cefepime placebo, Cefepime, Doripenem, Doripenem placebo, Amoxicillin/clavulanate potassium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Months to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Little Rock, Arkansas • Cleveland, Ohio • Toledo, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Oct 3, 2026, 11:00 AM EDT
Completed Phase 4 Interventional Results available

Lopinavir/Ritonavir (Kaletra) PK in Children

NCT00810108
View directory record Official record
Conditions
HIV/AIDS Treatment, HIV Infections
Interventions
lopinavir/ritonavir (Kaletra®) tablets
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
6 Years to 17 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
San Diego, California • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 6, 2012 · Synced Oct 3, 2026, 11:00 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children

NCT01196988
View directory record Official record
Conditions
Influenza
Interventions
Influenza vaccine GSK2321138A, FluarixTM, Influenza vaccine GSK2604409A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 17 Years
Enrollment
3,027 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
14
States / cities
Sacramento, California • Boca Raton, Florida • Wichita, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 3, 2026, 11:00 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Rhinovirus Hospitalization and Investigation of Nasal-airway Omics (RHINO) Study

NCT07342582
View directory record Official record
Conditions
Rhinovirus
Interventions
Nasal Swab Healthy Surveillance, Nasal Swab Sick Samples, Nasal Swab Hospitalized Cohort, Sick Follow-up Survey, Older Cohort Control Group, Procedural Comfort or Care
Diagnostic Test · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Up to 17 Years
Enrollment
670 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 3, 2026, 11:00 AM EDT
Completed Phase 3 Interventional

Terbinafine Compared to Griseofulvin in Children With Tinea Capitis

NCT00117767
View directory record Official record
Conditions
Tinea Capitis
Interventions
Terbinafine hydrochloride (HCl), Griseofulvin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
4 Years to 12 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 3, 2026, 11:00 AM EDT
Completed Phase 1 Interventional

Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox

NCT00001125
View directory record Official record
Conditions
HIV Infections, Chickenpox
Interventions
Varicella Virus Vaccine (Live)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
22
States / cities
Long Beach, California • Los Angeles, California • Torrance, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 3, 2026, 11:00 AM EDT
Completed No phase listed Observational

Observation of HIV-Infected Children Receiving Protease Inhibitor and Reverse Transcriptase Inhibitor

NCT00001826
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 3, 2026, 11:00 AM EDT